Class IIOngoing
Levothyroxine Sodium Tablets recall
FDA recall D-0656-2026 · initiated Jun 8, 2026
By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jul 8, 2026How we research
ACCORD HEALTHCARE, INC. recalled Levothyroxine Sodium Tablets in Jun 2026 — an FDA Class II recall (D-0656-2026) because Subpotent Drug.
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
Subpotent Drug
Details
- Product
- Levothyroxine Sodium Tablets, USP, 300 mcg (0.3mg), 90 Tablets bottles, Rx only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: lntas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-458-15.
- Recalling company
- ACCORD HEALTHCARE, INC.
- Classification
- Class II
- Status
- Ongoing
- Type
- Voluntary: Firm initiated
- Distribution
- US Nationwide.
- Initiated
- Jun 8, 2026
- FDA report date
- Jul 8, 2026
Frequently asked
- Was Levothyroxine Sodium Tablets recalled?
- ACCORD HEALTHCARE, INC. recalled Levothyroxine Sodium Tablets in Jun 2026 — an FDA Class II recall (D-0656-2026) because Subpotent Drug. May cause temporary or medically reversible harm; low probability of serious harm.
- Why was Levothyroxine Sodium Tablets recalled?
- Per the FDA enforcement record, the reason for recall D-0656-2026 was: Subpotent Drug
- Is a recalled Levothyroxine Sodium Tablets dangerous to take?
- An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
- Which lots of Levothyroxine Sodium Tablets are affected?
- Distribution: US Nationwide.. The affected lot numbers and expiration dates are listed in the official FDA enforcement record for recall D-0656-2026, initiated Jun 2026.